Lancet neurology
The most recent articles from:
Lancet Neurol
-
Multicenter Study Observational Study
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset with those who started 4-6 years after disease onset. ⋯ National Health and Medical Research Council Australia and MS Society UK.